Hong Chen, Wei Jianping, Zhou Tao, Wang Xia, Cai Jing
Department of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
Onco Targets Ther. 2022 Jun 10;15:651-657. doi: 10.2147/OTT.S364566. eCollection 2022.
Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion.
We report the case of a 45-year-old female patient who was diagnosed with lung adenocarcinoma and underwent right upper lobectomy and postoperative adjuvant chemotherapy. After 13 months, the patient's lung lesions progressed. Next-generation sequencing of venous blood and lung tissues confirmed an FGFR2-ERC1 fusion, and she received chemotherapy and immunotherapy. Two months later, the patient's lung lesions progressed again. Based on the target effect of anlotinib on FGFR, the patient was subsequently treated with anlotinib, and the progression-free survival interval exceeded 8.0 months.
These findings showed that patients with lung adenocarcinoma carrying an FGFR2-ERC1 fusion gene may benefit from anlotinib. This case provided evidence to support the use of anlotinib in the treatment of NSCLC patients with FGFR fusion gene subtypes.
非小细胞肺癌（NSCLC）中的成纤维细胞生长因子受体（FGFR）融合是小基因组事件。目前，对于携带FGFR融合的NSCLC患者尚无标准治疗策略。
我们报告了一例45岁女性患者，她被诊断为肺腺癌并接受了右上叶切除术及术后辅助化疗。13个月后，患者肺部病变进展。对静脉血和肺组织进行的二代测序证实存在FGFR2-ERC1融合，她接受了化疗和免疫治疗。两个月后，患者肺部病变再次进展。基于安罗替尼对FGFR的靶向作用，该患者随后接受安罗替尼治疗，无进展生存期超过8.0个月。
这些发现表明，携带FGFR2-ERC1融合基因的肺腺癌患者可能从安罗替尼中获益。该病例为支持安罗替尼用于治疗具有FGFR融合基因亚型的NSCLC患者提供了证据。
